

# Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

## Anti-Human CD4 (VIT4) Antibody, PE Conjugated

RRID:AB\_871684

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-092-373, RRID:AB\_871684

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_871684](http://antibodyregistry.org/AB_871684)

**Proper Citation:** Miltenyi Biotec Cat# 130-092-373, RRID:AB\_871684

**Target Antigen:** Human CD4 (VIT4)

**Clonality:** unknown

**Comments:** Discontinued: 2021; manufacturer recommendations:  
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-214. (RRID:AB\_2726025).

**Antibody Name:** Anti-Human CD4 (VIT4) Antibody, PE Conjugated

**Description:** This unknown targets Human CD4 (VIT4)

**Target Organism:** human

**Antibody ID:** AB\_871684

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-092-373

**Record Creation Time:** 20250820T064449+0000

**Record Last Update:** 20250821T005014+0000

### Ratings and Alerts

No rating or validation information has been found for Anti-Human CD4 (VIT4) Antibody, PE Conjugated.

**Warning:** Discontinued: 2021

Discontinued: 2021; manufacturer recommendations:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-214.

(RRID:AB\_2726025). **Warning:** Discontinued: 2018

Discontinued: 2021; manufacturer recommendations:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-214.

(RRID:AB\_2726025).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Andrews JM, et al. (2019) Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. EBioMedicine, 46, 170.